 Blueprint Medicines Corp NASDAQ:BPMC Wedbush boosted their Q2 2020 earnings per share estimates for Blueprint Medicines in a research report issued on Tuesday, July 14th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of 2.00 for the quarter, up from their prior estimate of 2.09. Wedbush has ... 